Factors influencing the therapeutic effect of muscle afferent block for oromandibular dystonia and dyskinesia: implications for their distinct pathophysiology.
Oromandibular dystonia (OMD) is a focal dystonia manifested by involuntary masticatory and/or lingual muscle contractions. Muscle afferent block (MAB) by injecting anaesthetic and alcohol intramuscularly is recently used for the treatment of OMD. To study the factors affecting the efficacy of MAB, 44 patients with OMD were treated by local injection of lidocaine and ethanol. They were divided into four groups (spastic, rhythmic, dyskinetic, and task-specific) according to the pattern of incisal movement and involuntary contraction. We used a clinical scaling protocol in terms of four parameters (mastication, speech, pain, and discomfort) to evaluate the change of symptoms objectively. The relationship of improvement in clinical scores with various parameters was assessed statistically. The overall objective improvement was 60.2 +/- 29.5%. The scores decreased significantly (P<0.0001, paired t-test) after MAB. The maximal incisal velocity significantly correlated inversely with the clinical improvement, and MAB was particularly effective for spastic contraction. Dyskinetic and rhythmic groups showed variable and significantly less improvements than the spastic group. MAB is highly effective for OMD, but not for the patients with dyskinetic symptoms. The jaw movement pattern is an important factor for predicting the outcome. The difference in the response to MAB in OMD and oral and/or orofacial dyskinesia suggests the distinct pathophysiology between the two.
Yoshida
K
K
Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Japan. kyoshida@kuhp.kyoto-u.ac.jp
Kaji
R
R
Shibasaki
H
H
Iizuka
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000627:therapeutic use; D002492:Central Nervous System Depressants / Q000008:administration & dosage / Q000627:therapeutic use; D020820:Dyskinesias / Q000503:physiopathology / Q000628:therapy; D020821:Dystonic Disorders / Q000145:classification / Q000503:physiopathology / Q000628:therapy*; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008012:Lidocaine / Q000008:administration & dosage / Q000627:therapeutic use; D016014:Linear Models; D008297:Male; D008334:Mandible / Q000503:physiopathology; D008409:Mastication / Q000502:physiology; D008410:Masticatory Muscles / Q000187:drug effects / Q000503:physiopathology*; D016555:Matched-Pair Analysis; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D019148:Neuromuscular Blockade / Q000379:methods*; D010147:Pain Measurement; D013035:Spasm / Q000503:physiopathology / Q000628:therapy; D013060:Speech / Q000502:physiology; D013223:Statistics as Topic; D014060:Tongue Diseases / Q000503:physiopathology / Q000628:therapy*
D000779:Anesthetics, Local; D002492:Central Nervous System Depressants; D000431:Ethanol; D008012:Lidocaine